fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Search » Aurobindo Pharma Ltd

Aurobindo Pharma Ltd

Updated on January 15, 2020

Stock/Share Code - AUROPHARMA

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 201903 Annual Report Page No: 147)

Below is the details of AUROPHARMA Aurobindo Pharma Ltd

Market Cap₹26,361 Cr.
Current Price ₹432.55 as on 10 Dec 19
52 Week High / Low Price₹838 / ₹389.35
Face Value₹1
Stock P/E15.95
Book Value₹206.07
Dividend Yield0.56 %
ROCE14.92 %
ROE14.42 %
Sales Growth (3yrs)10.21 %
SectorPharmaceuticals
IndustryPharmaceuticals - Indian - Bulk Drugs & Formln
Listed onBSE  AND  NSE
Company WebsiteCompany Website
Pros:
Cons: The company has delivered a poor growth of 11.51% over past five years. Company has high debtors of 155.79 days.

Aurobindo Pharma Ltd Price Chart

Aurobindo Pharma Ltd Price Chart

Aurobindo Pharma Ltd Peer Comparison in Pharmaceuticals

S.No. Name CMP Rs. P/E Mar Cap Rs.Cr. Div Yld % NP Qtr Rs.Cr. Qtr Profit Var % Qtr Sales Var % Sales Qtr Rs.Cr. ROCE %
1. Sun Pharma.Inds. ₹170.05 24.93 ₹107,934.08 Cr. 0.61 ₹1,064.09 Cr. 57.62 17.09 8123.35 11.19
2. Dr Reddy's Labs ₹2,897.5 17.68 ₹48,412.38 Cr. 0.69 ₹1,106.8 Cr. 113.54 26.07 4812.80 12.42
3. Cipla ₹453.05 22.78 ₹37,626.53 Cr. 0.64 ₹474.5 Cr. 25.85 9.57 4395.78 10.94
4. Piramal Enterp. ₹1,611.6 17.30 ₹36,008.74 Cr. 1.43 ₹554.69 Cr. 17.26 14.61 3603.56 9.42
5. Biocon ₹289.65 43.30 ₹33,798 Cr. 0.18 ₹215.7 Cr. -24.60 19.02 1572.20 13.39
6. Torrent Pharma. ₹13.65 37.89 ₹32,128.11 Cr. 0.90 ₹244 Cr. 36.31 5.86 2005.00 12.66
7. Aurobindo Pharma 15.95 ₹26,361.38 Cr. 0.56 ₹398.13 Cr. 4.51 1.62 3221.66 14.92
8. Cadila Health. ₹260.95 16.83 ₹26,018.42 Cr. 1.38 ₹107.2 Cr. -35.02 13.69 3366.60 15.35

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Aurobindo Pharma Ltd Fundamentals

Quarterly Results

Quarterly reports are issued by companies every three months. Most companies have a financial year-end of Mar. 31 and quarters that end on June 30, Sept. 30, Dec. 31 and March 31.

Standalone Figures in Rs. Crores

Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019
Sales2,5212,4202,1883,0742,6862,3552,5593,1703,2483,2813,0793,222
YOY Sales Growth %4.98%-1.12%-9.93%27.54%6.54%-2.7%16.93%3.14%20.91%39.32%20.32%1.62%
Expenses1,8871,8401,7002,0352,0221,8772,1622,5632,6502,5462,5282,590
Material Cost %47.35%46.5%44.92%39.83%46.69%46.77%51.48%50.63%51.89%47.91%50.09%50.46%
Employee Cost %9.15%10.43%11.87%8.83%10.54%13.48%12.48%10.47%10.77%11.03%12.26%11.61%
Operating Profit6345804891,039664478397607598734550631
OPM %25%24%22%34%25%20%16%19%18%22%18%20%
Other Income2951122934634137283034
Interest10910121317243141353225
Depreciation71738390909294101109109115118
Profit before tax582549407966595375282479585618433522
Tax %24%17%24%22%25%18%20%21%21%26%24%24%
Net Profit441455307753444308225381464460330398
EPS in Rs7.537.785.2512.857.585.263.846.507.917.855.646.80
NotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotes

Profit & Loss

The profit and loss (P&L) statement is a financial statement that summarizes the revenues, costs and expenses incurred during a specified period, usually a fiscal quarter or year. The P&L statement is synonymous with the income statement. These records provide information about a company's ability or inability to generate profit" by increasing revenue, reducing costs or both. Some refer to the P&L statement as a statement of profit and loss, income statement, statement of operations, statement of financial results or income, earnings statement or expense statement.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019TTM
Sales2,2762,7493,1954,1304,2775,4247,1088,0699,1589,60710,27012,25812,829
Sales Growth %21.93%20.8%16.23%29.24%3.57%26.81%31.06%13.51%13.5%4.91%6.9%19.36%%
Expenses1,9172,5002,4973,1733,7044,4665,1875,8166,7057,2157,6009,83810,315
Material Cost %59.58%59%54.76%53.29%58.89%55.51%49.01%46.81%46.85%48.37%44.43%50.41%%
Manufacturing Cost %11.06%9.91%9.97%10.34%11.42%11.06%9.37%9.69%9.8%9.83%10.35%10.61%%
Employee Cost %6.41%6.34%7.18%7.35%8.51%7.95%7.23%8.29%8.81%9.65%11.02%11.12%%
Other Cost %7.16%15.66%6.25%5.84%7.78%7.81%7.36%7.29%7.76%7.25%8.2%8.11%%
Operating Profit3592506989575739581,9222,2532,4532,3922,6702,4202,514
OPM %16%9%22%23%13%18%27%28%27%25%26%20%20%
Other Income1197517229-30027736518711881189229
Interest598163552682502891322294553231133
Depreciation758295125143171186245263286355413452
Profit before tax345161712805-1385631,5191,9402,1482,1792,3431,9652,159
Tax %16%20%26%26%69%12%23%22%24%22%23%22%
Net Profit291129526594-434961,1721,5161,6271,7071,8131,5301,652
EPS in Rs5.352.329.352.010.008.4019.8525.5327.8028.7330.9426.1128.20
Dividend Payout %6%19%5%10%-68%9%7%9%9%9%8%10%

Compounded Sales Growth

  • 10 Years:: 16.12%
  • 5 Years:: 11.51%
  • 3 Years:: 10.21%
  • TTM:: 19.12%

Compounded Profit Growth

  • 10 Years:: 28.53%
  • 5 Years:: 5.56%
  • 3 Years:: -1.87%
  • TTM:: 21.61%

Return on Equity

  • 10 Years:: 17.33%
  • 5 Years:: -4.79%
  • 3 Years:: -15.40%
  • 1 Year:: -44.50%

Balance Sheet

A balance sheet is a financial statement that reports a company's assets, liabilities and shareholders' equity at a specific point in time, and provides a basis for computing rates of return and evaluating its capital structure. It is a financial statement that provides a snapshot of what a company owns and owes, as well as the amount invested by shareholders. It is used alongside other important financial statements such as the income statement and statement of cash flows in conducting fundamental analysis or calculating financial ratios.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Sep 2019
Share Capital27272829292929295959595959
Equity Capital26.8826.8827.8629.1129.1129.1229.1529.258.5258.5958.5958.5958.59
Reserves1,1941,2941,8862,5402,4642,9103,9835,3306,8078,3789,92411,29212,016
Borrowings1,7562,1151,9452,3182,7942,7822,9253,2854,1653,0543,7194,5203,728
Other Liabilities5386177519718691,2461,6571,6101,7951,8662,4742,7102,676
Trade Payables354.82415.11514.27750.92610.15927.71276.581233.031423.661366.531811.271966.981760.27
Total Liabilities3,5144,0534,6105,8596,1566,9678,59410,25412,82713,35616,17618,58118,478
Fixed Assets8278731,0451,3501,6272,0121,9382,1902,5683,2123,3934,1504,290
Gross Block1134.481261.731526.881955.172363.272907.493008.823507.542830.783758.184292.185446.15
Accumulated Depreciation307.4388.86481.54605.28736.53895.581070.881317.53262.65546.56899.211296.45
CWIP1252864995375581662042277429071,144789740
Investments2882693714936297088731,0131,1831,6821,9682,3392,476
Other Assets2,2742,6252,6943,4793,3434,0815,5806,8248,3337,5569,67111,30310,972
Inventories651.23735.52944.821261.021219.261431.731711.812145.052431.62433.623409.233971.264296.39
Trade receivables798.971105.671151.351480.291426.281730.592970.123708.944380.973773.634468.235232.074809.69
Cash Equivalents239.3286.944.56122.2114.01114.579.7211.13330.8133.64245.975.77232.1
Loans n Advances584.78696.6593.67418.79504.4496.65408.06511.87899.07995.961239.881569.09359.58
Other Assets etc000196.56178.61307.68479.93447.49290.6318.96308.21454.631274.61
Total Assets3,5144,0534,6105,8596,1566,9678,59410,25412,82713,35616,17618,58118,478

Cash Flows

Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow.

Standalone Figures in Rs. Crores

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Cash from Operating Activity10553462455046253285902,457922527
Profit from operations351.77382.12737.42977.85517.21955.61935.192316.372482.472672.12420.43
Working Capital Changes-202.95-338.39-243.54-556.2915.34-214.82-1268.12-1300.05457.02-1219.73-1411.6
Taxes paid-43.35-38.85-147.5-176.99-28.5-115.86-339.04-425.91-482.29-529.97-482.12
Cash from Investing Activity-12-302-408-569-534-295-401-624-1,542-991-1,297
Fixed Assets Purchased-132.56-289.45-341.88-516.49-401.19-165.79-148.65-544-1019.6-975.77-890.06
Fixed Assets Sold1.681.0117.792.760.511.6510.312.042.09255.63.04
Investments purchased-85.22-69.27-73.13-200.19-153.2900-197.54-540.75-257.35-358.1
Investments sold170.9748.17038.81023.320028.7100
Cash from Financing Activity-185161-14443-78-229-3135-1,329440599
Proceeds from Shares1.5305.441.0800.823.456.766.660.230.06
Proceeds from Borrowings0443.52180.31622.061112.88287.18101.39377.510990.62951.72
Repayment of Borrowings-112.58-48.12-107.88-89.8-148.7-352.34-7.03-110.3-1156.54-237.79-65.17
Interest Paid-58.68-55.4-56.36-32.98-68.17-97.63-69.7-58.91-41.93-49.24-127.33
Dividends Paid-15.72-39.31-28.83-47.47-33.82-67.43-59.55-152.7-113.95-219.4-146.02
Net Cash Flow-92-136-75118-108101-1051-414371-171

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Ratios

Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
ROCE %14%7%21%20%9%15%29%27%24%20%19%15%
Debtor Days128147132131122116153168175143159156
Inventory Turnover3.803.963.803.743.454.094.524.184.003.953.523.32

Announcements & News

Recent Announcements

How to Invest in Mutual Funds SIP Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.
  2. Complete your Registration and KYC Process
  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest! Get Started
  4. Invest in Mutual Funds which invests in Aurobindo Pharma Ltd & Get More Returns than Bank Deposit

Disclaimer:
All efforts have been made to ensure the information provided here is accurate as per time to time filling by company to exchanges. However, no guarantees are made regarding correctness of data. Investors are advised to validate/check information with exchanges or companies website before making any investment decisions.